2nd Nordic Mantle-Cell Lymphoma protocol Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A To evaluate the haemostatic effect of N8-GP during surgical procedures in patients with haemophilia A

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The effect of liraglutide compared to sitagliptin, both in combination with metformin in subjects with type 2 diabetes. A 26-week, randomised, open-label, active comparator, three-armed, parallel-group, multi-centre, multi-national trial To assess and compare the efficacy (as assessed by change from baseline in HbA1c) after 26 weeks of adding liraglutide versus sitagliptin to the pre-trial metformin treatment in subjects with type 2 d...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 26-week randomised, controlled, open label, multicentre, multinational, treat to target trial investigating the impact of dietary intervention on weight change and the relationship between weight change and baseline body mass index (BMI) in subjects with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin therapy with insulin detemir in combination with metformin To investigate if treat-to-target treatment with insulin detemir once-daily (OD) combined with metformin accompanied with dietary intervention is superior to treat-to-target treatment with insulin det...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 2-es típusú cukorbetegeknek szájon át adott szemaglutid hatásosságát és biztonságosságát empagliflozinhoz (Jardiance®) viszonyítva értékelő vizsgálat To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 25 mg empagliflozin, both in combination with metformin, on glycaemic control in subjects with type 2 diabetes mellitus

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A placebo-controlled trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis To assess the effects of rFXIII on mucosal healing

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on metformin ± other oral antidiabetic drug(s) ± basal insulin To compare the efficacy of insulin detemir in combination with metformin and diet/exercise versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise in controllin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes To confirm the effect of treatment with meal-time faster-acting insulin aspart in terms of glycaemic control by comparing it to meal-time NovoRapid®, both in combination with insulin degludec using a ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + NovoRapid®, all in a basal/bolus regimen in subjects with type 1 diabetes To assess glucose control with respect to HbA1c after 16 weeks of treatment with SIBA (D) QD + NovoRapid® or SIBA (E) QD + NovoRapid® compared with that of insulin glargine QD + NovoRapid®, all in a b...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune